Welcome to our dedicated page for G1 Therapeutics news (Ticker: GTHX), a resource for investors and traders seeking the latest updates and insights on G1 Therapeutics stock.
G1 Therapeutics, Inc. (Nasdaq: GTHX) is a commercial-stage oncology biopharmaceutical company committed to developing next-generation therapies to improve the lives of cancer patients. The company is based in Research Triangle Park, N.C., and leverages its proprietary kinase drug discovery platform to advance a pipeline of innovative compounds. G1's flagship product, COSELA® (trilaciclib), has been approved by the FDA to decrease the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC).
In addition to COSELA, G1 Therapeutics is actively developing and evaluating trilaciclib in combination with other anti-cancer therapies. One notable project is the global, multi-center, randomized, placebo-controlled Phase 3 trial known as PRESERVE 2, which investigates trilaciclib in patients with metastatic triple-negative breast cancer (mTNBC). Preliminary results have shown promising survival benefits, indicating trilaciclib’s potential to protect bone marrow and enhance patient outcomes during cytotoxic therapy.
The company also engages in strategic partnerships to broaden its impact. For instance, G1 Therapeutics has entered agreements with companies like Pepper Bio and Jupiter Bioventures to advance the clinical development and commercialization of lerociclib, another promising CDK4/6 inhibitor. These collaborations aim to explore lerociclib's efficacy in treating various cancers, including HCC and radioprotection uses.
On the financial front, G1 Therapeutics reported revenues of $82.5 million for the full year 2023, reflecting significant growth from $51.3 million in the previous year. The company's ongoing commitment to innovation and strategic collaborations underscores its role as a key player in oncology therapeutics.
For more information, visit G1 Therapeutics and follow them on Twitter and LinkedIn.
G1 Therapeutics, Inc. (Nasdaq: GTHX) has appointed Dr. Norman E. “Ned” Sharpless to its Board of Directors. Dr. Sharpless, who has nearly 30 years of experience in oncology, is a co-founder of G1 and previously served as Director of the National Cancer Institute. His expertise is expected to enhance G1's development and commercialization of the oncology drug COSELA (trilaciclib), which has shown promise across multiple tumor types. The appointment reflects G1's commitment to transforming cancer care and advancing innovative treatment options.
G1 Therapeutics, Inc. (GTHX) will host a webcast and conference call for a corporate and financial update on August 3, 2022, at 8:30 a.m. ET. This event marks an opportunity for investors to gain insights into the company’s current performance and future outlook.
G1 Therapeutics focuses on developing therapies for cancer, with its first product, COSELA® (trilaciclib), aimed at improving patient outcomes across various solid tumors.
On July 13, 2022, G1 Therapeutics announced that the China National Medical Products Administration has conditionally approved COSELA (trilaciclib) for preventing chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer patients. This approval will trigger a $13 million milestone payment to G1, with potential total milestones of up to $156 million, along with double-digit royalties on annual net sales in China. This partnership with Simcere addresses a significant medical need in a growing market, with 4.2 million new cancer patients projected in China by 2040.
G1 Therapeutics (GTHX) announced the grant of inducement stock options for 40,400 shares and 26,800 restricted stock units (RSUs) to six newly hired employees. This move, aligned with the Amended and Restated 2021 Inducement Equity Incentive Plan, follows Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $5.17 and a ten-year term, with a four-year vesting schedule. The RSUs also have a four-year vesting plan. This initiative aims to attract talent necessary for G1's ongoing commitment to developing cancer therapies, including its product COSELA®.
G1 Therapeutics, Inc. (Nasdaq: GTHX) announces the appointment of Jacks Lee to its Board of Directors. Lee brings over 30 years of experience in the life sciences, currently serving as Senior VP at Merck & Co. His expertise in manufacturing and supply chain management is expected to aid G1 in commercializing COSELA® (trilaciclib) for lung cancer and expanding its clinical trials. CEO Jack Bailey emphasized Lee's strategic and operational background as a significant asset to the company's growth and innovation in oncology.
G1 Therapeutics announced the completion of enrollment in its Phase 3 clinical trial (PRESERVE 1) of trilaciclib for treating metastatic colorectal cancer (mCRC), with 326 patients randomized. This trial aims to assess myeloprotection during chemotherapy, crucial as mCRC treatment often leads to dose delays impacting survival. The primary endpoint evaluates the duration and occurrence of severe neutropenia. Initial data, including primary endpoint results, are expected in early 2023. Positive outcomes may expedite regulatory approval by the FDA.
G1 Therapeutics (GTHX) presented a post-hoc analysis at the 2022 ASCO meeting, revealing that patients receiving trilaciclib experienced significantly fewer myelosuppressive events compared to those on placebo. Key findings include a 75% reduction in severe neutropenia and a 100% reduction in severe thrombocytopenia. The study highlights the potential of trilaciclib to enhance chemotherapy outcomes for patients with extensive-stage small cell lung cancer (ES-SCLC).
G1 Therapeutics (GTHX) granted inducement stock options for 1,400 shares and 800 restricted stock units (RSUs) to a new employee under the Amended and Restated 2021 Inducement Equity Incentive Plan. The stock options, exercisable at $4.48 per share, have a ten-year term with a four-year vesting schedule, while RSUs vest over four years. This grant aligns with Nasdaq Listing Rule 5635(c)(4), permitting equity awards for new hires to incentivize their employment. G1 Therapeutics focuses on developing therapies for cancer treatment, including their product COSELA™.
G1 Therapeutics, Inc. (GTHX) has been awarded Triangle Business Journal's 2022 Company of the Year (Public) at the Life Sciences Award ceremony. This recognition highlights the company's growth in the oncology sector and its contributions to the Life Sciences community in Research Triangle Park. G1 recently received FDA approval for COSELA™, aimed at protecting small-cell lung cancer patients from chemotherapy side effects. The company is currently advancing its clinical trials for COSELA across various solid tumors.
G1 Therapeutics (GTHX) announced its CEO, Jack Bailey, will present at the H.C. Wainwright & Co. Global Investment Conference, with a virtual presentation scheduled for May 24, 2022, at 7:00 AM EDT. This event will be accessible both in-person and online. G1 Therapeutics focuses on developing next-generation oncology therapies, including its first commercial product, COSELA™ (trilaciclib). The company has a robust clinical pipeline targeting various solid tumors, such as colorectal, breast, lung, and bladder cancers.
FAQ
What is the current stock price of G1 Therapeutics (GTHX)?
What is the market cap of G1 Therapeutics (GTHX)?
What does G1 Therapeutics, Inc. specialize in?
What is COSELA® (trilaciclib)?
What is the PRESERVE 2 trial?
Where is G1 Therapeutics, Inc. located?
Who are G1 Therapeutics' key partners?
What recent financial achievements has G1 Therapeutics reported?
What is lerociclib?
How can I get more information about G1 Therapeutics?
What types of cancer are G1 Therapeutics’ therapies targeting?
What are G1 Therapeutics’ future goals?
